ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.
暂无分享,去创建一个
[1] P. Bonate,et al. Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz‐112638) After Single Doses, Multiple Doses, and Food in Healthy Volunteers , 2011, Journal of clinical pharmacology.
[2] P. Bonate,et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. , 2010, Blood.
[3] Laurie A. Smith,et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models , 2010, Nature Medicine.
[4] R. Scheule,et al. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy , 2010, Journal of Inherited Metabolic Disease.
[5] J. Shayman,et al. Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice , 2009, Hepatology.
[6] Daniel Grinberg,et al. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. , 2009, Blood cells, molecules & diseases.
[7] S. Gummuluru,et al. Glycosphingolipid Composition of Human Immunodeficiency Virus Type 1 (HIV-1) Particles Is a Crucial Determinant for Dendritic Cell-Mediated HIV-1 trans-Infection , 2009, Journal of Virology.
[8] Shufeng Zhou. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.
[9] J. M. Aerts,et al. Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring , 2008, Journal of Inherited Metabolic Disease.
[10] C. Ficicioglu. Review of miglustat for clinical management in Gaucher disease type 1 , 2008, Therapeutics and clinical risk management.
[11] Joel L Sussman,et al. Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. , 2007, The Journal of biological chemistry.
[12] J. Shayman,et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. , 2007, Molecular genetics and metabolism.
[13] Seng H. Cheng,et al. Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes , 2007, Diabetes.
[14] P. Kaplan,et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. , 2006, Archives of pediatrics & adolescent medicine.
[15] C. Mignot,et al. Type 2 Gaucher disease: 15 new cases and review of the literature , 2006, Brain and Development.
[16] J. Charrow,et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease , 2005, American journal of hematology.
[17] P. Kaplan,et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. , 2004, Seminars in hematology.
[18] N. Radin. Treatment of Gaucher disease with an enzyme inhibitor , 1996, Glycoconjugate Journal.
[19] P. Kaplan,et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements , 2004, European Journal of Pediatrics.
[20] D. Witte,et al. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. , 2003, The American journal of pathology.
[21] N. Radin,et al. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come? , 2001, European journal of biochemistry.
[22] P. Kaplan,et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.
[23] R. Brady,et al. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase. , 2000, Kidney international.
[24] J. K. Park,et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.
[25] A. Kulkarni,et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. , 2000, The Journal of clinical investigation.
[26] A. Abe,et al. Inhibitors of glucosylceramide synthase. , 2000, Methods in enzymology.
[27] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[28] A. Abe,et al. Improved inhibitors of glucosylceramide synthase. , 1992, The Journal of biological chemistry.
[29] G. Grabowski,et al. Gaucher disease: gene frequencies and genotype/phenotype correlations. , 1997, Genetic testing.
[30] B. Ganem,et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. , 1995, Journal of lipid research.
[31] J. Dambrosia,et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.
[32] R. Brady,et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Santarsiero,et al. Enantioselective Synthesis of α-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon. , 1990 .
[34] N. Radin,et al. Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain. , 1980, Chemistry and physics of lipids.
[35] N. Radin,et al. A possible therapeutic approach to Krabbe's globoid leukodystrophy and the status of cerebroside synthesis in the disorder. , 1972, Research communications in chemical pathology and pharmacology.